Psyence Group (TSE:PSYG) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Psyence Group has announced a deal to sell its 11.13% interest in PsyLabs to Psyence Biomed, which will bolster Psyence Biomed’s capabilities in developing psychedelic-based therapeutics. The agreement, valued at $1.1 million in common stock, is contingent on certain conditions including approvals and a product development milestone by PsyLabs.
For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.